Loading…
Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients
There is limited data on the prevalence of SARS-COV-2 in sarcoidosis patients and the underlying parameters linked to severity. We aimed to conduct a national multicenter study to explore the prevalence of SARS-COV-2 in sarcoidosis patients and investigate its impact on hospitalization and infection...
Saved in:
Published in: | Sarcoidosis, vasculitis, and diffuse lung diseases vasculitis, and diffuse lung diseases, 2024-12, Vol.41 (4), p.e2024055 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | |
container_issue | 4 |
container_start_page | e2024055 |
container_title | Sarcoidosis, vasculitis, and diffuse lung diseases |
container_volume | 41 |
creator | Kotsiou, Ourania Kirgou, Paraskevi Tzouvelekis, Argyrios Kolilekas, Lykourgos Manali, Effrosyni Papiris, Spyros Papakosta, Despina Antoniou, Katerina Papanikolaou, Ilias Steiropoulos, Paschalis Tomos, Ioannis Karampitsakos, Theodoros Levounets, Anastasia Fouka, Evagelia Spyropoulos, Georgios Mastrodimou, Semeli Papaioannou, Ourania Kallieri, Maria Kosmidou, Nikoleta Bizymi, Nikoleta Zikos, Nikolaos Dimeas, Ilias Malli, Foteini Daniil, Zoe |
description | There is limited data on the prevalence of SARS-COV-2 in sarcoidosis patients and the underlying parameters linked to severity. We aimed to conduct a national multicenter study to explore the prevalence of SARS-COV-2 in sarcoidosis patients and investigate its impact on hospitalization and infection rates, describe the characteristics of the infected population and assess the role of these characteristics in determining the likelihood of infection or hospitalization.
We recruited all the adult sarcoidosis patients with who were examined across eight Greek Health Interstitial Lung Disease Referral Centers from the beginning of the pandemic until August 1, 2022. All the data was collected using structured questionnaires.
530 sarcoidosis patients with a mean age of 54±12 years, 60% of whom were females, were recruited. 43% of them were under corticosteroid treatment, and 39% were under additional immunosuppression. 18% of Greek sarcoidosis patients were infected by the virus, which is a lower rate than the general population. The infection was mainly mild. Only one-fifth of the infected sarcoidosis patients required hospitalization, and no deaths or ICU admissions were recorded. Vaccination was found to be associated with a reduced likelihood of infection. Younger age, a longer period since diagnosis, abnormal PET-CT findings, and immunosuppression were associated with an increased probability of infection.
The COVID-19 infection rate among Greek sarcoidosis patients was lower than the general population. Fewer than 20% needed hospitalization. There were no deaths or ICU admissions. Vaccination reduces the likelihood of infection. Younger age, longer diagnosis, abnormal PET-CT findings, and immunosuppression increased the chance of infection. |
doi_str_mv | 10.36141/svdld.v41i4.15661 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146611521</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146611521</sourcerecordid><originalsourceid>FETCH-LOGICAL-p561-e4f9a4b10959fe67aaeb9d47dc0da65c66323ba25dd5d3e859d116373c66943c3</originalsourceid><addsrcrecordid>eNpNkE1Lw0AYhBdRbK3-AQ-yRy-p-2Y_0j2WolWoVGwRb2Gz-wZWk2zMJgX_vQEreJph5mEOQ8g1sDlXIOAuHlzl5gcBXsxBKgUnZJpKniaQ6ffTf35CLmL8YEwtJGPnZMK1klJqmJLnlw4PpsLGIg0l3S1fd8lq-5ak1Dcl2t6HhprG0TD0NtQYx5iuO8RPGk1ng3ch-khb03ts-nhJzkpTRbw66ozsH-73q8dks10_rZabpJUKEhSlNqIApqUuUWXGYKGdyJxlzihpleIpL0wqnZOO40JqB6B4xsdGC275jNz-zrZd-Bow9nnto8WqMg2GIeYcxHgGyBRG9OaIDkWNLm87X5vuO_97gP8AFp5ehw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146611521</pqid></control><display><type>article</type><title>Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients</title><source>Open Access: PubMed Central</source><creator>Kotsiou, Ourania ; Kirgou, Paraskevi ; Tzouvelekis, Argyrios ; Kolilekas, Lykourgos ; Manali, Effrosyni ; Papiris, Spyros ; Papakosta, Despina ; Antoniou, Katerina ; Papanikolaou, Ilias ; Steiropoulos, Paschalis ; Tomos, Ioannis ; Karampitsakos, Theodoros ; Levounets, Anastasia ; Fouka, Evagelia ; Spyropoulos, Georgios ; Mastrodimou, Semeli ; Papaioannou, Ourania ; Kallieri, Maria ; Kosmidou, Nikoleta ; Bizymi, Nikoleta ; Zikos, Nikolaos ; Dimeas, Ilias ; Malli, Foteini ; Daniil, Zoe</creator><creatorcontrib>Kotsiou, Ourania ; Kirgou, Paraskevi ; Tzouvelekis, Argyrios ; Kolilekas, Lykourgos ; Manali, Effrosyni ; Papiris, Spyros ; Papakosta, Despina ; Antoniou, Katerina ; Papanikolaou, Ilias ; Steiropoulos, Paschalis ; Tomos, Ioannis ; Karampitsakos, Theodoros ; Levounets, Anastasia ; Fouka, Evagelia ; Spyropoulos, Georgios ; Mastrodimou, Semeli ; Papaioannou, Ourania ; Kallieri, Maria ; Kosmidou, Nikoleta ; Bizymi, Nikoleta ; Zikos, Nikolaos ; Dimeas, Ilias ; Malli, Foteini ; Daniil, Zoe</creatorcontrib><description>There is limited data on the prevalence of SARS-COV-2 in sarcoidosis patients and the underlying parameters linked to severity. We aimed to conduct a national multicenter study to explore the prevalence of SARS-COV-2 in sarcoidosis patients and investigate its impact on hospitalization and infection rates, describe the characteristics of the infected population and assess the role of these characteristics in determining the likelihood of infection or hospitalization.
We recruited all the adult sarcoidosis patients with who were examined across eight Greek Health Interstitial Lung Disease Referral Centers from the beginning of the pandemic until August 1, 2022. All the data was collected using structured questionnaires.
530 sarcoidosis patients with a mean age of 54±12 years, 60% of whom were females, were recruited. 43% of them were under corticosteroid treatment, and 39% were under additional immunosuppression. 18% of Greek sarcoidosis patients were infected by the virus, which is a lower rate than the general population. The infection was mainly mild. Only one-fifth of the infected sarcoidosis patients required hospitalization, and no deaths or ICU admissions were recorded. Vaccination was found to be associated with a reduced likelihood of infection. Younger age, a longer period since diagnosis, abnormal PET-CT findings, and immunosuppression were associated with an increased probability of infection.
The COVID-19 infection rate among Greek sarcoidosis patients was lower than the general population. Fewer than 20% needed hospitalization. There were no deaths or ICU admissions. Vaccination reduces the likelihood of infection. Younger age, longer diagnosis, abnormal PET-CT findings, and immunosuppression increased the chance of infection.</description><identifier>ISSN: 2532-179X</identifier><identifier>EISSN: 2532-179X</identifier><identifier>DOI: 10.36141/svdld.v41i4.15661</identifier><identifier>PMID: 39655591</identifier><language>eng</language><publisher>Italy</publisher><ispartof>Sarcoidosis, vasculitis, and diffuse lung diseases, 2024-12, Vol.41 (4), p.e2024055</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39655591$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kotsiou, Ourania</creatorcontrib><creatorcontrib>Kirgou, Paraskevi</creatorcontrib><creatorcontrib>Tzouvelekis, Argyrios</creatorcontrib><creatorcontrib>Kolilekas, Lykourgos</creatorcontrib><creatorcontrib>Manali, Effrosyni</creatorcontrib><creatorcontrib>Papiris, Spyros</creatorcontrib><creatorcontrib>Papakosta, Despina</creatorcontrib><creatorcontrib>Antoniou, Katerina</creatorcontrib><creatorcontrib>Papanikolaou, Ilias</creatorcontrib><creatorcontrib>Steiropoulos, Paschalis</creatorcontrib><creatorcontrib>Tomos, Ioannis</creatorcontrib><creatorcontrib>Karampitsakos, Theodoros</creatorcontrib><creatorcontrib>Levounets, Anastasia</creatorcontrib><creatorcontrib>Fouka, Evagelia</creatorcontrib><creatorcontrib>Spyropoulos, Georgios</creatorcontrib><creatorcontrib>Mastrodimou, Semeli</creatorcontrib><creatorcontrib>Papaioannou, Ourania</creatorcontrib><creatorcontrib>Kallieri, Maria</creatorcontrib><creatorcontrib>Kosmidou, Nikoleta</creatorcontrib><creatorcontrib>Bizymi, Nikoleta</creatorcontrib><creatorcontrib>Zikos, Nikolaos</creatorcontrib><creatorcontrib>Dimeas, Ilias</creatorcontrib><creatorcontrib>Malli, Foteini</creatorcontrib><creatorcontrib>Daniil, Zoe</creatorcontrib><title>Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients</title><title>Sarcoidosis, vasculitis, and diffuse lung diseases</title><addtitle>Sarcoidosis Vasc Diffuse Lung Dis</addtitle><description>There is limited data on the prevalence of SARS-COV-2 in sarcoidosis patients and the underlying parameters linked to severity. We aimed to conduct a national multicenter study to explore the prevalence of SARS-COV-2 in sarcoidosis patients and investigate its impact on hospitalization and infection rates, describe the characteristics of the infected population and assess the role of these characteristics in determining the likelihood of infection or hospitalization.
We recruited all the adult sarcoidosis patients with who were examined across eight Greek Health Interstitial Lung Disease Referral Centers from the beginning of the pandemic until August 1, 2022. All the data was collected using structured questionnaires.
530 sarcoidosis patients with a mean age of 54±12 years, 60% of whom were females, were recruited. 43% of them were under corticosteroid treatment, and 39% were under additional immunosuppression. 18% of Greek sarcoidosis patients were infected by the virus, which is a lower rate than the general population. The infection was mainly mild. Only one-fifth of the infected sarcoidosis patients required hospitalization, and no deaths or ICU admissions were recorded. Vaccination was found to be associated with a reduced likelihood of infection. Younger age, a longer period since diagnosis, abnormal PET-CT findings, and immunosuppression were associated with an increased probability of infection.
The COVID-19 infection rate among Greek sarcoidosis patients was lower than the general population. Fewer than 20% needed hospitalization. There were no deaths or ICU admissions. Vaccination reduces the likelihood of infection. Younger age, longer diagnosis, abnormal PET-CT findings, and immunosuppression increased the chance of infection.</description><issn>2532-179X</issn><issn>2532-179X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNkE1Lw0AYhBdRbK3-AQ-yRy-p-2Y_0j2WolWoVGwRb2Gz-wZWk2zMJgX_vQEreJph5mEOQ8g1sDlXIOAuHlzl5gcBXsxBKgUnZJpKniaQ6ffTf35CLmL8YEwtJGPnZMK1klJqmJLnlw4PpsLGIg0l3S1fd8lq-5ak1Dcl2t6HhprG0TD0NtQYx5iuO8RPGk1ng3ch-khb03ts-nhJzkpTRbw66ozsH-73q8dks10_rZabpJUKEhSlNqIApqUuUWXGYKGdyJxlzihpleIpL0wqnZOO40JqB6B4xsdGC275jNz-zrZd-Bow9nnto8WqMg2GIeYcxHgGyBRG9OaIDkWNLm87X5vuO_97gP8AFp5ehw</recordid><startdate>20241210</startdate><enddate>20241210</enddate><creator>Kotsiou, Ourania</creator><creator>Kirgou, Paraskevi</creator><creator>Tzouvelekis, Argyrios</creator><creator>Kolilekas, Lykourgos</creator><creator>Manali, Effrosyni</creator><creator>Papiris, Spyros</creator><creator>Papakosta, Despina</creator><creator>Antoniou, Katerina</creator><creator>Papanikolaou, Ilias</creator><creator>Steiropoulos, Paschalis</creator><creator>Tomos, Ioannis</creator><creator>Karampitsakos, Theodoros</creator><creator>Levounets, Anastasia</creator><creator>Fouka, Evagelia</creator><creator>Spyropoulos, Georgios</creator><creator>Mastrodimou, Semeli</creator><creator>Papaioannou, Ourania</creator><creator>Kallieri, Maria</creator><creator>Kosmidou, Nikoleta</creator><creator>Bizymi, Nikoleta</creator><creator>Zikos, Nikolaos</creator><creator>Dimeas, Ilias</creator><creator>Malli, Foteini</creator><creator>Daniil, Zoe</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20241210</creationdate><title>Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients</title><author>Kotsiou, Ourania ; Kirgou, Paraskevi ; Tzouvelekis, Argyrios ; Kolilekas, Lykourgos ; Manali, Effrosyni ; Papiris, Spyros ; Papakosta, Despina ; Antoniou, Katerina ; Papanikolaou, Ilias ; Steiropoulos, Paschalis ; Tomos, Ioannis ; Karampitsakos, Theodoros ; Levounets, Anastasia ; Fouka, Evagelia ; Spyropoulos, Georgios ; Mastrodimou, Semeli ; Papaioannou, Ourania ; Kallieri, Maria ; Kosmidou, Nikoleta ; Bizymi, Nikoleta ; Zikos, Nikolaos ; Dimeas, Ilias ; Malli, Foteini ; Daniil, Zoe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p561-e4f9a4b10959fe67aaeb9d47dc0da65c66323ba25dd5d3e859d116373c66943c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kotsiou, Ourania</creatorcontrib><creatorcontrib>Kirgou, Paraskevi</creatorcontrib><creatorcontrib>Tzouvelekis, Argyrios</creatorcontrib><creatorcontrib>Kolilekas, Lykourgos</creatorcontrib><creatorcontrib>Manali, Effrosyni</creatorcontrib><creatorcontrib>Papiris, Spyros</creatorcontrib><creatorcontrib>Papakosta, Despina</creatorcontrib><creatorcontrib>Antoniou, Katerina</creatorcontrib><creatorcontrib>Papanikolaou, Ilias</creatorcontrib><creatorcontrib>Steiropoulos, Paschalis</creatorcontrib><creatorcontrib>Tomos, Ioannis</creatorcontrib><creatorcontrib>Karampitsakos, Theodoros</creatorcontrib><creatorcontrib>Levounets, Anastasia</creatorcontrib><creatorcontrib>Fouka, Evagelia</creatorcontrib><creatorcontrib>Spyropoulos, Georgios</creatorcontrib><creatorcontrib>Mastrodimou, Semeli</creatorcontrib><creatorcontrib>Papaioannou, Ourania</creatorcontrib><creatorcontrib>Kallieri, Maria</creatorcontrib><creatorcontrib>Kosmidou, Nikoleta</creatorcontrib><creatorcontrib>Bizymi, Nikoleta</creatorcontrib><creatorcontrib>Zikos, Nikolaos</creatorcontrib><creatorcontrib>Dimeas, Ilias</creatorcontrib><creatorcontrib>Malli, Foteini</creatorcontrib><creatorcontrib>Daniil, Zoe</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Sarcoidosis, vasculitis, and diffuse lung diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kotsiou, Ourania</au><au>Kirgou, Paraskevi</au><au>Tzouvelekis, Argyrios</au><au>Kolilekas, Lykourgos</au><au>Manali, Effrosyni</au><au>Papiris, Spyros</au><au>Papakosta, Despina</au><au>Antoniou, Katerina</au><au>Papanikolaou, Ilias</au><au>Steiropoulos, Paschalis</au><au>Tomos, Ioannis</au><au>Karampitsakos, Theodoros</au><au>Levounets, Anastasia</au><au>Fouka, Evagelia</au><au>Spyropoulos, Georgios</au><au>Mastrodimou, Semeli</au><au>Papaioannou, Ourania</au><au>Kallieri, Maria</au><au>Kosmidou, Nikoleta</au><au>Bizymi, Nikoleta</au><au>Zikos, Nikolaos</au><au>Dimeas, Ilias</au><au>Malli, Foteini</au><au>Daniil, Zoe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients</atitle><jtitle>Sarcoidosis, vasculitis, and diffuse lung diseases</jtitle><addtitle>Sarcoidosis Vasc Diffuse Lung Dis</addtitle><date>2024-12-10</date><risdate>2024</risdate><volume>41</volume><issue>4</issue><spage>e2024055</spage><pages>e2024055-</pages><issn>2532-179X</issn><eissn>2532-179X</eissn><abstract>There is limited data on the prevalence of SARS-COV-2 in sarcoidosis patients and the underlying parameters linked to severity. We aimed to conduct a national multicenter study to explore the prevalence of SARS-COV-2 in sarcoidosis patients and investigate its impact on hospitalization and infection rates, describe the characteristics of the infected population and assess the role of these characteristics in determining the likelihood of infection or hospitalization.
We recruited all the adult sarcoidosis patients with who were examined across eight Greek Health Interstitial Lung Disease Referral Centers from the beginning of the pandemic until August 1, 2022. All the data was collected using structured questionnaires.
530 sarcoidosis patients with a mean age of 54±12 years, 60% of whom were females, were recruited. 43% of them were under corticosteroid treatment, and 39% were under additional immunosuppression. 18% of Greek sarcoidosis patients were infected by the virus, which is a lower rate than the general population. The infection was mainly mild. Only one-fifth of the infected sarcoidosis patients required hospitalization, and no deaths or ICU admissions were recorded. Vaccination was found to be associated with a reduced likelihood of infection. Younger age, a longer period since diagnosis, abnormal PET-CT findings, and immunosuppression were associated with an increased probability of infection.
The COVID-19 infection rate among Greek sarcoidosis patients was lower than the general population. Fewer than 20% needed hospitalization. There were no deaths or ICU admissions. Vaccination reduces the likelihood of infection. Younger age, longer diagnosis, abnormal PET-CT findings, and immunosuppression increased the chance of infection.</abstract><cop>Italy</cop><pmid>39655591</pmid><doi>10.36141/svdld.v41i4.15661</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2532-179X |
ispartof | Sarcoidosis, vasculitis, and diffuse lung diseases, 2024-12, Vol.41 (4), p.e2024055 |
issn | 2532-179X 2532-179X |
language | eng |
recordid | cdi_proquest_miscellaneous_3146611521 |
source | Open Access: PubMed Central |
title | Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T04%3A31%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20SARS-COV-2%20infection%20and%20outcomes%20in%20Greek%20sarcoidosis%20patients&rft.jtitle=Sarcoidosis,%20vasculitis,%20and%20diffuse%20lung%20diseases&rft.au=Kotsiou,%20Ourania&rft.date=2024-12-10&rft.volume=41&rft.issue=4&rft.spage=e2024055&rft.pages=e2024055-&rft.issn=2532-179X&rft.eissn=2532-179X&rft_id=info:doi/10.36141/svdld.v41i4.15661&rft_dat=%3Cproquest_pubme%3E3146611521%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p561-e4f9a4b10959fe67aaeb9d47dc0da65c66323ba25dd5d3e859d116373c66943c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3146611521&rft_id=info:pmid/39655591&rfr_iscdi=true |